IDS and mucopolysaccharidosis type 2: We propose to use this approach, which proved to be effective and safe, not only in patients with Hunter syndrome and Scheie syndrome, who develop HSR during ERT with idursulfase and laronidase, respectively, but also in ERT hypersensitivity in other types of MPS and in other rare diseases, being treated by recombinant enzyme medications.